Since Voeller and colleagues already described synergy between CD40 agonists and anti-GD2 therapy in neuroblastoma [161], the addition of TNF and CD40 agonists to the treatment regimen could prove a promising new strategy. The gene discussed is TNF; the disease is neuroblastoma.